|
|||||
|
|
| 肿瘤导向治疗的最新临床研究进展 | |
| 引用本文： | 孙志伟,高原,孙岩,俞炜源. 肿瘤导向治疗的最新临床研究进展[J]. 生物技术通讯, 2001, 12(1): 48-50,59 |
| 作者姓名： | 孙志伟 高原 孙岩 俞炜源 |
| 作者单位： | 1. 军事医学科学院生物工程研究所 2. 海军航空兵体检队 3. 北京空军466医院内四科 |
| 摘 要： | 20余年来，肿瘤的导向治疗研究经历了高潮和低潮的多次反复，终于在近几年取得了突破性进展，以Ritux-imab、Tractuzumab和DAB39IL-2为代表的抗肿瘤导向治疗制剂巳经通过FDA批准上市，展示出肿瘤导向治疗的光明前景。 |
| 关 键 词： | 肿瘤 导向治疗 抗体 人抗鼠抗体 毒素 核素 细胞因子 研究进展 |
Advances in clinicaltargeting therapy of cancer |
|
| SUN Zhi Wei,GAO Yuan,SUN Yan,YU Wei Yuan. Advances in clinicaltargeting therapy of cancer[J]. Letters in Biotechnology, 2001, 12(1): 48-50,59 | |
| Authors: | SUN Zhi Wei GAO Yuan SUN Yan YU Wei Yuan |
| Affiliation: | SUN Zhi?Wei 1,GAO Yuan 2,SUN Yan 3,YU Wei?Yuan 1 |
| Abstract: | Targeting therapy of cancer has been for more than 20 years through devious developmentes. Recently, it received break?through progress. The Food and Drug Administration just approved the Mabs Rituximab, Tractuzumab and the Chimeric toxin DAB389IL?2. These exciting results suggest that Targeting therapy may be applied in human malignant therapy. |
| Keywords: | tumor targeting therapy antibody HAMA toxin nuclide cytokine |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ | |